-

Charles River Laboratories Schedules Fourth-Quarter 2022 Earnings and 2023 Guidance Release and Conference Call

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) will release fourth-quarter and full-year 2022 financial results and provide 2023 guidance on Wednesday, February 22nd, before the market opens. A conference call has been scheduled to discuss this information on Wednesday, February 22nd, at 8:30 a.m. ET.

Investors will have the opportunity to listen to a live webcast of the conference call through the Investor Relations section of the Company's website at ir.criver.com. A replay will be accessible through the same website.

About Charles River

Charles River provides essential products and services to help pharmaceutical and biotechnology companies, government agencies and leading academic institutions around the globe accelerate their research and drug development efforts. Our dedicated employees are focused on providing clients with exactly what they need to improve and expedite the discovery, early-stage development and safe manufacture of new therapies for the patients who need them. To learn more about our unique portfolio and breadth of services, visit www.criver.com.

Contacts

Investor Relations:
Todd Spencer
Corporate Vice President, Investor Relations
781.222.6455
todd.spencer@crl.com

Charles River Laboratories International, Inc.

NYSE:CRL

Release Summary
Charles River Laboratories Schedules Fourth-Quarter 2022 Earnings and 2023 Guidance Release and Conference Call
Release Versions
$Cashtags

Contacts

Investor Relations:
Todd Spencer
Corporate Vice President, Investor Relations
781.222.6455
todd.spencer@crl.com

More News From Charles River Laboratories International, Inc.

Charles River Leverages Advanced Technology to Expedite Oncology Drug Discovery and Development

WILMINGTON, Mass.--(BUSINESS WIRE)--Ahead of AACR 2025, Charles River announces updates to its comprehensive portfolio to support the discovery and development of novel oncology drugs....

Charles River Laboratories Schedules First-Quarter 2025 Earnings Release and Conference Call

WILMINGTON, Mass.--(BUSINESS WIRE)--Charles River Laboratories schedules first-quarter 2025 earnings release and conference call...

Charles River and Valo Health Identify a Potential Therapeutic for Lupus Using Logica®, an AI-Powered Drug Discovery Platform

WILMINGTON, Mass. & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Charles River and Valo Health announce the identification of an advanceable product candidate for treatment of lupus and other autoimmune diseases....
Back to Newsroom